Lung cancer
Lung cancer occurs in the bronchial mucosa or glands, also known as bronchial lung cancer. In the past 50 years, many countries have reported that the incidence of lung cancer has increased significantly. Among male cancer patients, lung cancer has ranked first, and the incidence rate in women has also increased rapidly, accounting for the second or third most common malignant tumors in women. The male-female incidence ratio is 3~5:1, and the age of onset is mostly between 60-79 years old. The cause of lung cancer is still not completely clear. A large amount of data shows that long-term heavy smoking is an important pathogenic factor of lung cancer. For those who smoke more than 40 cigarettes a day for many years, the incidence of squamous cell carcinoma and undifferentiated cancer of the lung is 4 to 10 times higher than that of non-smokers. The incidence of lung cancer in urban residents is higher than that in rural areas, which may be related to air pollution and carcinogens contained in smoke. Therefore, non-smoking should be advocated and urban environmental sanitation work should be strengthened.
Related Drugs
Gemcitabine Hydrochloride for Injection
Indication: Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.
Manufacturer:
Lianyungang JARI Pharmaceutical Co., Ltd.
Gemcitabine Hydrochloride for Injection
Indication: Non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.
Manufacturer:
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Vinorelbine tartrate
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Manufacturer:
Guangzhou Hanfang Pharmaceutical Company Limited
Vinorelbine tartrate
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:
Qilu Pharmaceutical (Hainan) Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Hainan Zhuotai Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Shanxi Zhendong Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Chengdu Beite Denuo Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Shanxi PUDE Pharmaceutical Co., Ltd.